口服五价牛-人重配轮状病毒疫苗的排毒表明疫苗高接种率及G型G1的突出性
研究纳入301名按芬兰程序在2、3、5月龄接种RotaTeq®的婴儿,首次剂量后5-10天93%的接种者排毒。G1为主要排毒基因型,常与P[8]伴随,是长期排毒中唯一发现的基因型,排毒可持续至8月龄。作者认为排毒是疫苗接种成功的标志,五价疫苗作用类似单价G1疫苗。
要点
- 首次剂量后5-10天93%的接种者排出疫苗相关病毒颗粒。
- G1为主要排毒基因型,常与P[8]伴随,是长期排毒中唯一基因型。
- 含G1疫苗病毒排毒可持续至8月龄,五价疫苗作用类似单价G1疫苗。
核心结论
- RotaTeq®疫苗来源病毒的排毒是疫苗接种成功的标志。
- G1伴或不伴P[8]的密集排毒反映有效增殖,可能是诱导保护性免疫的重要因素。
- 含G1疫苗病毒的排毒可持续至8月龄。
- 这些结果提示五价疫苗在很大程度上像单价G1疫苗一样发挥作用。
研究设计与样本
- 研究纳入301名按芬兰程序在2、3和5月龄接种RotaTeq®疫苗的婴儿。
- 首次剂量后5-10天及第三剂前0-7天采集粪便样本,若第二份样本阳性则在6周和12周后额外采集。
- 所有粪便样本用RT-PCR检测轮状病毒VP7、VP4和VP6。
- 父母在每次疫苗剂量后填写一周的症状日记。
主要发现
- 首次剂量后5-10天采集的一份样本中,93%的接种者排出疫苗相关病毒颗粒。
- G1是排毒中的主要基因型,常与P[8]伴随,并且是长期排毒中唯一发现的基因型。
- G4也常被检测到,而其他疫苗G型和牛型P[5]未检测到。
临床怎么用
- 作者认为RotaTeq®疫苗来源病毒的排毒是疫苗接种成功的标志。
- 作者认为G1伴或不伴P[8]的密集排毒反映有效增殖,可能是诱导保护性免疫的重要因素。
- 作者指出含G1疫苗病毒的排毒可持续至8月龄,五价疫苗作用类似单价G1疫苗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Live oral pentavalent bovine-human reassortant rotavirus (RV) vaccine, RotaTeq®, contains bovine rotaviruses reassorted with human G-types G1, G2, G3 and G4, and P-type P[8]. Shedding of RotaTeq® vaccine, as studied by RT-PCR, has been shown to be more common than initially reported, and may include formation of vaccine-derived double-reassortant G1P[8] RVs. We studied the extent and duration of RotaTeq® vaccine virus shedding, genotypes shed, and clinical symptoms associated with shedding. MATERIAL AND METHODS: We enrolled a total of 301 infants who received RotaTeq® vaccine according to Finnish schedule at 2, 3 and 5 months of age. Stool samples were collected 5-10 days after the first and 0-7 days before the third dose of the vaccine. Additional stool samples 6 and 12 weeks later were collected if the second stool sample was positive. All stools were studied with RT-PCR for RV VP7, VP4 and VP6. Parents filled a symptom diary for a week after each vaccine dose. RESULTS: We found that 93% of the vaccinees shed vaccine related viral particles in one sample taken 5-10 days after the first dose, indicating that stool shedding is very common and may be regarded as a marker of successful vaccination. Genotype G1 was the predominant genotype in shedding, often in association with P[8], and the only genotype found in long-term shedding. Also G4 was commonly detected whereas other vaccine G-types and bovine-type P[5] were not. CONCLUSIONS: Shedding of RotaTeq® vaccine-derived viruses is a sign for successful vaccination. Intense shedding of G1 with or without P[8]reflects effective multiplication and may be an important factor in the induction of protective immunity. Shedding of G1 containing vaccine viruses may be prolonged up to 8 months of age. These results suggest that the pentavalent vaccine functions largely like a monovalent G1 vaccine. Eudra-CT: 2014-004252-60.
引用
- Markkula J, Hemming-Harlo M, Vesikari T, et al. Shedding of oral pentavalent bovine-human reassortant rotavirus vaccine indicates high uptake rate of vaccine and prominence of G-type G1. Vaccine. 2019. PMID: 31862199. doi:10.1016/j.vaccine.2019.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。